Dyne Therapeutics (NASDAQ:DYN) CEO Sells $60,789.96 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) CEO John Cox sold 3,311 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $18.36, for a total value of $60,789.96. Following the completion of the transaction, the chief executive officer owned 370,834 shares in the company, valued at $6,808,512.24. This trade represents a 0.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $17.29 on Friday. The company has a current ratio of 19.92, a quick ratio of 22.25 and a debt-to-equity ratio of 0.17. The business’s 50 day moving average is $18.34 and its two-hundred day moving average is $18.63. Dyne Therapeutics, Inc. has a 12-month low of $8.06 and a 12-month high of $25.00. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of -5.37 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period last year, the firm posted ($1.05) EPS. Research analysts expect that Dyne Therapeutics, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Evercore set a $33.00 target price on Dyne Therapeutics in a research report on Friday. Chardan Capital reiterated a “buy” rating and set a $38.00 target price on shares of Dyne Therapeutics in a research report on Monday, March 9th. Sanford C. Bernstein boosted their target price on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday. JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 20th. Finally, Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Dyne Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $35.00.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $50 price target on Dyne Therapeutics while raising several earnings estimates, suggesting analysts remain confident in the company’s longer-term prospects.
• Positive Sentiment: Lifesci Capital also lifted its earnings forecasts for Dyne Therapeutics across multiple periods, pointing to improved expectations for future results.
• Neutral Sentiment: Dyne Therapeutics’ average brokerage rating remains Moderate Buy, indicating Wall Street sentiment is still constructive overall. Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: The company recently reported a quarterly loss that was slightly better than expected, which is supportive but not a major catalyst on its own.
• Negative Sentiment: CEO John Cox, CFO Erick Lucera, and insider Douglas Kerr each sold shares this week. The filings say the sales were tied to tax withholding on equity vesting, but insider selling can still weigh on investor sentiment.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors have recently modified their holdings of the company. Hilton Head Capital Partners LLC purchased a new stake in shares of Dyne Therapeutics during the 1st quarter worth approximately $26,000. Chung Wu Investment Group LLC purchased a new stake in shares of Dyne Therapeutics during the 3rd quarter worth approximately $30,000. Strs Ohio purchased a new stake in shares of Dyne Therapeutics during the 4th quarter worth approximately $51,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics during the 4th quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after acquiring an additional 2,465 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor?mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.